Compare Summit Therapeutics Inc (SMMT) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs ProShares UltraPro QQQ ETF — how do they compare? Summit Therapeutics Inc trades at $17.54 (market cap $13.71B), while ProShares UltraPro QQQ ETF trades at $81.34 (market cap $38.74B). The key difference: ProShares UltraPro QQQ ETF is far larger — about 2.8× Summit Therapeutics Inc's market cap, and ProShares UltraPro QQQ ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and ProShares UltraPro QQQ ETF for 24 Days on average.
| SMMT | TQQQ | |
|---|---|---|
Market Cap | $13.71B | $38.74B |
Volume | 6,173,057 | 65,384,797 |
Sector | Health | Leveraged / Inverse |
52-Week High | $26.38 | $87.22 |
52-Week Low | $12.43 | $37.89 |
Typical Hold Time | 16 Days | 24 Days |
Enterprise Value | $13.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
TQQQ trades at $81.16, down 2.92% on the day, with technical indicators showing a bullish overall signal despite recent selling pressure. The leveraged ETF structure amplifies both gains and losses, with recent news highlighting hidden costs beyond the stated 0.82% expense ratio. Support levels are established at $78 and $76, while resistance sits at $83 and $85.
The outlook for TQQQ remains tied to Nasdaq-100 performance and tech sector momentum, though volatility decay and financing costs present significant long-term risks. Current technical positioning suggests potential for near-term upside if support holds, but investors should be cautious of amplified losses during market downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
